WO1998013031A3 - Medicinal aerosol formulations comprising budesonide - Google Patents

Medicinal aerosol formulations comprising budesonide Download PDF

Info

Publication number
WO1998013031A3
WO1998013031A3 PCT/US1997/016869 US9716869W WO9813031A3 WO 1998013031 A3 WO1998013031 A3 WO 1998013031A3 US 9716869 W US9716869 W US 9716869W WO 9813031 A3 WO9813031 A3 WO 9813031A3
Authority
WO
WIPO (PCT)
Prior art keywords
budesonide
aerosol formulations
medicinal aerosol
hydrofluoroalkane
sorbitant
Prior art date
Application number
PCT/US1997/016869
Other languages
French (fr)
Other versions
WO1998013031A2 (en
Inventor
Nayna Govind
Philip A Jinks
Danna L Ross
Gary H Ward
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10800599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998013031(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL97332422A priority Critical patent/PL332422A1/en
Priority to SK383-99A priority patent/SK38399A3/en
Priority to EP97943453.7A priority patent/EP0932397B2/en
Priority to CA002266431A priority patent/CA2266431A1/en
Priority to AU44926/97A priority patent/AU732985B2/en
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Priority to DE69735497T priority patent/DE69735497T2/en
Priority to JP10515789A priority patent/JP2001501209A/en
Priority to BR9712125-8A priority patent/BR9712125A/en
Publication of WO1998013031A2 publication Critical patent/WO1998013031A2/en
Publication of WO1998013031A3 publication Critical patent/WO1998013031A3/en
Priority to NO991407A priority patent/NO991407D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical aerosol formulation, suitable for administration by oral or nasal inhalation, containing a suspension of particulate budesonide, hydrofluoroalkane propellant and, optionally, additional hydrofluoroalkane propellants, surfactant selected from oleic acid, sorbitant oleates and lecithin, and adjuvant have a Kauri-butanol value of at least 10.
PCT/US1997/016869 1996-09-27 1997-09-23 Medicinal aerosol formulations comprising budesonide WO1998013031A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR9712125-8A BR9712125A (en) 1996-09-27 1997-09-23 Pharmaceutical formulation in aerosol, use of a mixture, pharmaceutical product, and process of administration of budesonide to a patient
SK383-99A SK38399A3 (en) 1996-09-27 1997-09-23 Medicinal aerosol formulations comprising budesonide
EP97943453.7A EP0932397B2 (en) 1996-09-27 1997-09-23 Medicinal aerosol formulations comprising budesonide
CA002266431A CA2266431A1 (en) 1996-09-27 1997-09-23 Medicinal aerosol formulations comprising budesonide
AU44926/97A AU732985B2 (en) 1996-09-27 1997-09-23 Medicinal aerosol formulations comprising budesonide
PL97332422A PL332422A1 (en) 1996-09-27 1997-09-23 Aerosol-type therapeutic preparations containing budesonide
DE69735497T DE69735497T2 (en) 1996-09-27 1997-09-23 MEDICAL AEROSOL FORMULATIONS CONTAINING BUDESONID
JP10515789A JP2001501209A (en) 1996-09-27 1997-09-23 Medical aerosol composition containing budesonide
NO991407A NO991407D0 (en) 1996-09-27 1999-03-23 Drug aerosol formulations comprising budesonide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9620187.6A GB9620187D0 (en) 1996-09-27 1996-09-27 Medicinal aerosol formulations
GB9620187.6 1996-09-27

Publications (2)

Publication Number Publication Date
WO1998013031A2 WO1998013031A2 (en) 1998-04-02
WO1998013031A3 true WO1998013031A3 (en) 1998-08-27

Family

ID=10800599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016869 WO1998013031A2 (en) 1996-09-27 1997-09-23 Medicinal aerosol formulations comprising budesonide

Country Status (21)

Country Link
EP (1) EP0932397B2 (en)
JP (1) JP2001501209A (en)
KR (1) KR20000048646A (en)
AR (1) AR009370A1 (en)
AT (1) ATE320246T1 (en)
AU (1) AU732985B2 (en)
BR (1) BR9712125A (en)
CA (1) CA2266431A1 (en)
CZ (1) CZ102799A3 (en)
DE (1) DE69735497T2 (en)
ES (1) ES2259447T3 (en)
GB (1) GB9620187D0 (en)
HU (1) HUP0000795A3 (en)
ID (1) ID22523A (en)
MY (1) MY130946A (en)
NO (1) NO991407D0 (en)
PL (1) PL332422A1 (en)
PT (1) PT932397E (en)
SK (1) SK38399A3 (en)
WO (1) WO1998013031A2 (en)
ZA (1) ZA978303B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863910A (en) * 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (en) 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
IT1303788B1 (en) * 1998-11-25 2001-02-23 Chiesi Farma Spa MEDICINAL AEROSOL FORMULATIONS.
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (en) 1999-07-23 2002-09-09 Chiesi Farma Spa OPTIMIZED FORMULATIONS CONSTITUTED BY SOLUTIONS OF STEROIDS GIVEN BY INHALATION.
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
IT1317846B1 (en) 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
ME00220B (en) 2000-05-22 2010-10-10 Chiesi Farm Spa Stable pharmaceutical solution formulations for pressurised metered dose inhalers
ES2222294T3 (en) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. OPTIMIZED FORMULATION OF TOBRAMYCIN FOR ADMINISTRATION IN THE FORM OF AEROSOL.
GB0311701D0 (en) * 2003-05-21 2003-06-25 Karib Kemi Pharm Liited Improved metered dose inhaler product
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
ES2317306T3 (en) * 2004-10-12 2009-04-16 Generics (Uk) Limited PROCEDURE FOR THE PREPARATION OF FORMULATIONS IN AEROSOL IN SUSPENSION, IN WHICH THE PARTICLES ARE FORMED BY PRECIPITATION WITHIN AN AEROSOL FLASK.
EP1949891A1 (en) * 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
ES2259915B1 (en) * 2005-03-15 2007-12-16 Laboratorio Aldo-Union, S.A. NEW STABLE FORMULATION OF AEROSOLS IN SUSPENSION AND PROCEDURE OF OBTAINING.
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
CN102362859A (en) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 Budesonide aerosol preparation using hydrofluoroalkane as propellent
CN103655473A (en) * 2011-10-27 2014-03-26 江苏长风药业有限公司 Budesonide aerosol preparation with hydrofluoroalkane used as propellant
CN109646400A (en) * 2018-12-25 2019-04-19 上海信谊百路达药业有限公司 A kind of budesonide inhalation aerosol and preparation method thereof
CN112891328A (en) * 2021-04-12 2021-06-04 上海方予健康医药科技有限公司 Preparation method of budesonide suspension for inhalation
CN113768906B (en) * 2021-10-25 2023-05-09 上海方予健康医药科技有限公司 Novel glucocorticoid inhalation aerosol and pharmaceutical assembly

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011495A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Novel vehicle gas mixtures and their use in medical preparations
EP0504112A2 (en) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmaceutical aerosol formulations
EP0533731A1 (en) * 1990-06-04 1993-03-31 Ethyl Corporation Process for halogenating aromatic compounds
WO1994021229A1 (en) * 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
EP0633019A1 (en) * 1993-07-08 1995-01-11 ASTA Medica Aktiengesellschaft Pressurized gas packagings using polyoxyethylene glyceryl fatty acid esters as suspension stabilizers and valve lubricants
WO1995008603A1 (en) * 1993-09-24 1995-03-30 E.I. Du Pont De Nemours And Company Compositions including two hydrofluorocarbons
WO1995027476A1 (en) * 1994-04-11 1995-10-19 The Center For Innovative Technology Hydrofluorocarbon propellant containing medicinal aerosols
WO1996019198A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) † 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
ATE150296T1 (en) † 1991-12-18 1997-04-15 Minnesota Mining & Mfg AEROSOL COMPOSITIONS FOR MEDICINAL SUSPENSIONS
DE4230876A1 (en) † 1992-03-17 1993-09-23 Asta Medica Ag COMPRESSED GAS PACKS USING POLYOXYETHYLENE GLYCERYL OLEATES
GB9425160D0 (en) † 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011495A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Novel vehicle gas mixtures and their use in medical preparations
EP0533731A1 (en) * 1990-06-04 1993-03-31 Ethyl Corporation Process for halogenating aromatic compounds
EP0504112A2 (en) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmaceutical aerosol formulations
WO1994021229A1 (en) * 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
EP0633019A1 (en) * 1993-07-08 1995-01-11 ASTA Medica Aktiengesellschaft Pressurized gas packagings using polyoxyethylene glyceryl fatty acid esters as suspension stabilizers and valve lubricants
WO1995008603A1 (en) * 1993-09-24 1995-03-30 E.I. Du Pont De Nemours And Company Compositions including two hydrofluorocarbons
WO1995027476A1 (en) * 1994-04-11 1995-10-19 The Center For Innovative Technology Hydrofluorocarbon propellant containing medicinal aerosols
WO1996019198A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside

Also Published As

Publication number Publication date
AU732985B2 (en) 2001-05-03
MY130946A (en) 2007-07-31
HUP0000795A3 (en) 2000-09-28
AR009370A1 (en) 2000-04-12
HUP0000795A2 (en) 2000-08-28
EP0932397B1 (en) 2006-03-15
AU4492697A (en) 1998-04-17
NO991407L (en) 1999-03-23
CA2266431A1 (en) 1998-04-02
ZA978303B (en) 1999-03-15
PT932397E (en) 2006-07-31
EP0932397A2 (en) 1999-08-04
DE69735497D1 (en) 2006-05-11
NO991407D0 (en) 1999-03-23
CZ102799A3 (en) 1999-07-14
EP0932397B2 (en) 2014-04-02
KR20000048646A (en) 2000-07-25
BR9712125A (en) 1999-08-31
PL332422A1 (en) 1999-09-13
ID22523A (en) 1999-10-28
ATE320246T1 (en) 2006-04-15
DE69735497T2 (en) 2006-08-24
ES2259447T3 (en) 2006-10-01
JP2001501209A (en) 2001-01-30
WO1998013031A2 (en) 1998-04-02
GB9620187D0 (en) 1996-11-13
SK38399A3 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
WO1998013031A3 (en) Medicinal aerosol formulations comprising budesonide
CA2402300A1 (en) Fluorocarbon aerosol medicaments
CA2206782A1 (en) Aerosol drug formulations
AU4260496A (en) Propellant mixture for aerosol formulation
CA2125665A1 (en) Medicaments
CA2125666A1 (en) Medicaments
EP1277467A3 (en) Non-chlorofluorocarbon aerosol formulations
CA2206736A1 (en) Aerosol formulations of peptides and proteins
CA2111002A1 (en) Non-Chlorofluorocarbon Aerosol Formulations
AU3038197A (en) Aerosol formulations
NZ240237A (en) An aerosol formulation (free of surfactant) for treatment of asthma comprising: a hydrofluorocarbon propellant, ethanol, and beclomethasone 17,21 dipropionate; preparation thereof
CA2416403A1 (en) A medicinal aerosol formulation
MY108748A (en) Medicaments
CA2317999A1 (en) Pharmaceutical formulation of fluticasone propionate
YU59899A (en) Medicinal aerosol products
GB2332372B (en) Pharmaceutical aerosol compositions
AU1534501A (en) Pharmaceutical formulations of salmeterol
CA2446562A1 (en) Pharmaceutical formulation of fluticasone propionate
MX9604004A (en) Aerosol drug formulations containing vitamin e.
TH33149A (en) Pharmaceutical aerosol formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

WWE Wipo information: entry into national phase

Ref document number: 334475

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/002568

Country of ref document: MX

Ref document number: 1997943453

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2266431

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2266431

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 38399

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV1999-1027

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 1998 515789

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997002589

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV1999-1027

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997943453

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997002589

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-1027

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1019997002589

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997943453

Country of ref document: EP